Hycamtin
Recurrent Small-cell Lung Cancer (SCLC)
GlaxoSmithKlinePhase 2
—
Rating in progress
Hycamtin in Recurrent Small-cell Lung Cancer (SCLC) is in the Floatz rating universe. The engine has not yet published a v0.2 rating for this asset. This page will update automatically once scoring completes.
Methodology v0.2 · Dormant